Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 1/20 | 0.43 |
| ▸ | NHERF1 | O14745 | 2/20 | 0.43 |
| ▸ | NPC1 | O15118 | 3/20 | 0.43 |
| ▸ | RAB9A | P51151 | 3/20 | 0.43 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | ESR1 | P03372 | 1/20 | 0.41 |
| ▸ | ESRRG | P62508 | 1/20 | 0.41 |
| ▸ | PYGL | P06737 | 2/20 | 0.41 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.40 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.40 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.40 |
| ▸ | FADS1 | O60427 | 1/20 | 0.40 |
| ▸ | GRM5 | P41594 | 1/20 | 0.40 |
| ▸ | TDP2 | O95551 | 1/20 | 0.40 |
| ▸ | AHR | P35869 | 1/20 | 0.40 |
| ▸ | MAOA | P21397 | 1/20 | 0.40 |
| ▸ | MAOB | P27338 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12332996 | 0.91 | F10 (0.46) | F10NHERF1NPC1RAB9ATRPV1 | |
| SCHEMBL13635579 | 0.89 | ALDH1A1 (0.48) | NHERF1NPC1RAB9ASMN1; SMN2TP53 | |
| SCHEMBL10059653 | 0.89 | NHERF1 (0.49) | F10NHERF1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL10059629 | 0.86 | KMT2A (0.48) | F10NHERF1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL16474830 | 0.85 | RAB9A (0.46) | NPC1RAB9ATRPV1SMN1; SMN2TP53 | |
| SCHEMBL10079099 | 0.85 | SRC (0.44) | NHERF1NPC1RAB9ASMN1; SMN2TP53 | |
| SCHEMBL16474849 | 0.84 | RXFP1 (0.41) | NPC1RAB9ASMN1; SMN2TP53KMT2A | |
| SCHEMBL16474854 | 0.84 | CA1 (0.45) | NPC1RAB9AKMT2A | |
| SCHEMBL10059639 | 0.84 | MAPT (0.44) | F10NHERF1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL10079838 | 0.82 | ESRRG (0.43) | NPC1RAB9ASMN1; SMN2TP53KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9290450-B2 | Compounds and methods for treating inflammatory and fibrotic disorders | INTERMUNE, INC. (US) | 2016-03-22 | — | — | US | disclosed |
| US-9290450-B2 | Compounds and methods for treating inflammatory and fibrotic disorders | INTERMUNE, INC. (US) | 2016-03-22 | — | — | US | disclosed |
| EP-2296653-B1 | COMPOUNDS AND METHODS FOR TREATING INFLAMMATORY AND FIBROTIC DISORDERS | INTERMUNE INC (US) | 2016-01-27 | — | — | EP | disclosed |
| US-8969347-B2 | Compounds and methods for treating inflammatory and fibrotic disorders | INTERMUNE, INC. | 2015-03-03 | — | — | US | disclosed |
| US-8969347-B2 | Compounds and methods for treating inflammatory and fibrotic disorders | INTERMUNE, INC. | 2015-03-03 | — | — | US | disclosed |
| US-20130102597-A1 | COMPOUNDS AND METHODS FOR TREATING INFLAMMATORY AND FIBROTIC DISORDERS | INTERMUNE, INC. (US) | 2013-04-25 | — | — | US | disclosed |
| US-20130102597-A1 | COMPOUNDS AND METHODS FOR TREATING INFLAMMATORY AND FIBROTIC DISORDERS | INTERMUNE, INC. (US) | 2013-04-25 | — | — | US | disclosed |
| US-8304413-B2 | Compounds and methods for treating inflammatory and fibrotic disorders | INTERMUNE, INC. (US) | 2012-11-06 | — | — | US | disclosed |
| US-8304413-B2 | Compounds and methods for treating inflammatory and fibrotic disorders | INTERMUNE, INC. (US) | 2012-11-06 | — | — | US | disclosed |
| US-20120014917-A1 | METHODS OF TREATING HIV PATIENTS WITH ANTI-FIBROTICS | UNIVERSITY OF MINNESOTA (US) | 2012-01-19 | — | — | US | disclosed |
| US-20110218515-A1 | Methods for Treating Acute Myocardial Infarctions and Associated Disorders | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2011-09-08 | — | — | US | disclosed |
| US-20110218515-A1 | Methods for Treating Acute Myocardial Infarctions and Associated Disorders | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2011-09-08 | — | — | US | disclosed |
| WO-2010135470-A1 | PIFENIDONE DERIVATIVES FOR TREATING BRONCHIAL ASTHMA | INTERMUNE, INC. (US) | 2010-11-25 | — | — | WO | disclosed |
| WO-2010132864-A1 | METHODS OF TREATING HIV PATIENTS WITH ANTI-FIBROTICS | INTERMUNE, INC. (US) | 2010-11-18 | — | — | WO | disclosed |
| US-20100190731-A1 | METHODS FOR TREATING ACUTE MYOCARDIAL INFARCTIONS AND ASSOCIATED DISORDERS | INTERMUNE, INC. | 2010-07-29 | — | — | US | disclosed |
| US-20100190731-A1 | METHODS FOR TREATING ACUTE MYOCARDIAL INFARCTIONS AND ASSOCIATED DISORDERS | INTERMUNE, INC. | 2010-07-29 | — | — | US | disclosed |
| WO-2010085805-A1 | METHODS FOR TREATING ACUTE MYOCARDIAL INFARCTIONS AND ASSOCIATED DISORDERS | INTERMUNE, INC. (US) | 2010-07-29 | — | — | WO | disclosed |
| US-20090318455-A1 | COMPOUNDS AND METHODS FOR TREATING INFLAMMATORY AND FIBROTIC DISORDERS | INTERMUNE, INC. (US) | 2009-12-24 | — | — | US | disclosed |
| US-20090318455-A1 | COMPOUNDS AND METHODS FOR TREATING INFLAMMATORY AND FIBROTIC DISORDERS | INTERMUNE, INC. (US) | 2009-12-24 | — | — | US | disclosed |
| WO-2009149188-A1 | COMPOUNDS AND METHODS FOR TREATING INFLAMMATORY AND FIBROTIC DISORDERS | INTERMUNE, INC. (US) | 2009-12-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100190731-A1 | METHODS FOR TREATING ACUTE MYOCARDIAL INFARCTIONS AND ASSOCIATED DISORDERS | TNNI3, FABP3, TNNT2 | F10 1968/4885NHERF1 2642/4885NPC1 2678/4885 |
| US-20130102597-A1 | COMPOUNDS AND METHODS FOR TREATING INFLAMMATORY AND FIBROTIC DISORDERS | MAP3K8, MAP3K1, MAP3K6 | F10 4234/4885NHERF1 3298/4885NPC1 3195/4885 |
| US-20090318455-A1 | COMPOUNDS AND METHODS FOR TREATING INFLAMMATORY AND FIBROTIC DISORDERS | MAP3K8, MAP3K1, MAP3K6 | F10 4234/4885NHERF1 3298/4885NPC1 3195/4885 |
| US-20120014917-A1 | METHODS OF TREATING HIV PATIENTS WITH ANTI-FIBROTICS | MMP1, MMP8, CCL11 | F10 3208/4885NHERF1 2597/4885NPC1 2054/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.